These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. Dopamine distribution and behavioral alterations resulting from dopamine infusion into the brain of the lesioned rat. Kroin JS, Kao LC, Zhang TJ, Penn RD, Klawans HL, Carvey PM. J Neurosurg; 1991 Jan 25; 74(1):105-11. PubMed ID: 1984488 [Abstract] [Full Text] [Related]
53. Biochemical and behavioral recovery in a rodent model of Parkinson's disease following stereotactic implantation of dopamine-containing liposomes. During MJ, Freese A, Deutch AY, Kibat PG, Sabel BA, Langer R, Roth RH. Exp Neurol; 1992 Feb 21; 115(2):193-9. PubMed ID: 1735466 [Abstract] [Full Text] [Related]
54. The efficacy of levodopa treatment declines in the course of Parkinson's disease: do nondopaminergic lesions play a role? Agid Y, Graybiel AM, Ruberg M, Hirsch E, Blin J, Dubois B, Javoy-Agid F. Adv Neurol; 1990 Feb 21; 53():83-100. PubMed ID: 1978522 [No Abstract] [Full Text] [Related]
55. Effects of D-2 agonists on the release of dopamine: localization of the mechanism of action. Timmerman W, De Vries JB, Westerink BH. Naunyn Schmiedebergs Arch Pharmacol; 1990 Dec 21; 342(6):650-4. PubMed ID: 1982893 [Abstract] [Full Text] [Related]
56. Infusion of Sydenham's chorea antibodies in striatum with up-regulated dopaminergic receptors: a pilot study to investigate the potential of SC antibodies to increase dopaminergic activity. Doyle F, Cardoso F, Lopes L, Mendes M, Dias F, Cruz L, Tavares R, Camargos A, Carneiro M, Dias-Lopes C, Chávez-Olórtegui C. Neurosci Lett; 2012 Aug 15; 523(2):186-9. PubMed ID: 22781496 [Abstract] [Full Text] [Related]
57. Importance of the calcium content infused during microdialysis for the effects induced by D2 agonists on the release of dopamine in the striatum of the rat. Timmerman W, Westerink BH. Neurosci Lett; 1991 Sep 30; 131(1):93-6. PubMed ID: 1686479 [Abstract] [Full Text] [Related]
58. The antiparkinsonian activity of dopamine agonists and their interaction with central dopamine receptor subtypes. Goldstein M, Lieberman AN, Takasugi N, Shimizu Y, Kuga S. Adv Neurol; 1990 Sep 30; 53():101-6. PubMed ID: 1978511 [No Abstract] [Full Text] [Related]
59. Circadian rhythm-dependent development of melatonin effects and tolerance to PHNO in rats. Munro JD, Martin-Iverson MT. Pharmacol Biochem Behav; 2000 Mar 30; 65(3):495-501. PubMed ID: 10683490 [Abstract] [Full Text] [Related]
60. Intraventricular infusion of Dopamine in Parkinson's disease. Horne MK, Butler EG, Gilligan BS, Wodak J, Stark RJ, Brazenor GA. Ann Neurol; 1989 Dec 30; 26(6):792-4. PubMed ID: 2604387 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]